Showing results (101-110 of 121) with videos related to
Sort By:
Pageof 13
The Journal of Rheumatology|October 1, 1992
Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritisO D Messina, J C Barreira, J R Zanchetta, et al.Calcified Tissue International|November 15, 2012
A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year dataMichael R McClung, Claude-Laurent Benhamou, Zulema Man, et al.Bone|November 27, 2013
Differing effects of denosumab and alendronate on cortical and trabecular boneRoger M Zebaze, Cesar Libanati, Matthew Austin, et al.Annals of Internal Medicine|March 7, 2007
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trialSusan L Greenspan, Henry G Bone, Mark P Ettinger, et al.Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|November 26, 2008
Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohortsBenito R Losada, Jose R Zanchetta, Cristiano Zerbini, et al.Bone|July 23, 2013
Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumabHarry K Genant, Cesar Libanati, Klaus Engelke, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 4, 2012
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year dataM R McClung, J R Zanchetta, A Racewicz, et al.Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|April 24, 2012
Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM studyMichael A Bolognese, Christence Stubbe Teglbjærg, Jose R Zanchetta, et al.Bone|October 9, 2007
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisPierre D Delmas, Michael R McClung, José R Zanchetta, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2018
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyMichael R McClung, Jacques P Brown, Adolfo Diez-Perez, et al.Pageof 13